Genentech to expand Hillsboro facility in Oregon, US

Published: 30-Mar-2015
Manufacturing Pharmaceutical

Will bring up to 100 new jobs to the state


Genentech, a Roche Group company headquartered in South San Francisco, CA, US, plans to invest more than US$125m to expand its fill/finish facility in Hillsboro, Oregon, US.

Larry Sanders, General Manager and Vice President, Hillsboro Technical Operations, said the investment in the biotechnology company's sterile production operations will result in the addition of up to 100 skilled manufacturing jobs in the greater Portland area over the next five years, potentially bringing the total number of Genentech jobs in Oregon to more than 500.

Genentech started operations in Hillsboro in April 2010. As well as the fill/finish facility, the site also includes a warehousing and distribution centre. Increasing manufacturing capacity will help the company meet growing demand for its products.

  • Companies:
  • Genentech
See more

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Read more
Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach

Trending Articles

  1. Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
  2. IMed supports K2 medical systems in their EU MDR transition Consultancy firm helps K2 navigate the complex regulatory process to achieve Article 97 compliance
  3. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  4. Pharmaceutics International bolsters its prefilled syringe production capabilities The aseptic and oral dosage CDMO has invested USD $3.6m into advanced labelling, fill/finish and automated visual inspection technologies at its Hunt Valley site in Maryland, US
  5. Ardena's Oss nanomedicine facility gains full GMP approval from the Dutch Healthcare Authority The pharmaceutical manufacturing facility can produce advanced nanoparticle drug delivery systems, including lipid-based, polymeric and metal oxide nanoparticles

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Research & Development

Scenic Biotech enters into genetic modifier collaboration with Genentech

Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
Manufacturing

Ensuring robust lyophilisation scale-up

SP Scientific announces the on-demand availability of a popular webinar by Jake Luoma of Genentech that discusses how controlled nucleation has emerged as a technology that promises improvements in lyophilisation throughput and consistency
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Optimising scale-up with flow process technologies

Speed of synthesis is of the essence when medicinal chemists invent new molecules, reports Sarah Houlton
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

ADCs: a more effective, less harmful, targeted approach

Antibody-drug conjugates could hold the key to delivering highly potent anticancer drugs more accurately to the tumour site with less damage to healthy cells
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Manufacturing

Genentech to expand California biologics manufacturing facilities

Investment of $285m will create more than 250 new jobs
Regulatory

A lucrative niche in orphan diseases?

The number of potential blockbuster drugs is in decline so many Big Pharma companies are looking to rare diseases to fill their pipelines because low sales volumes can be balanced out by premium prices.
Subscribe now